Portal Inflow Modulation by Somatostatin After Major Liver Resection: A Pilot Study
Related Experiment Video
Updated: Feb 17, 2026
Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
Published on: September 3, 2021
Rami Rhaiem1,2, Tullio Piardi1,2, Mikael Chetboun1,2
1Department of General, Digestive, and Endocrine Surgery, Robert Debré University-Hospital, Reims, France.
Abstract:
: Major hepatectomy (MH) can lead to an increasing portal vein pressure (PVP) and to lesions of the hepatic parenchyma. Several reports have assessed the deleterious effect of a high posthepatectomy PVP on the postoperative course of MH. Thus, several surgical modalities of portal inflow modulation (PIM) have been described. As for pharmacological modalities, experimental studies showed a potential efficiency of Somatostatin to reduce PVP and flow. To our knowledge, no previous clinical reports of PIM using somatostatin are available. Herein, we report the results of PIM using somatostatin in 10 patients who underwent MH with post-hepatectomy PVP > 20 mmHg. Our results suggest Somatostatin could be considered as an efficient reversible PIM when PVP decrease is above 2.5 mmHg.
Insights
Major hepatectomy (MH) can increase portal vein pressure (PVP). Somatostatin demonstrated potential as a reversible portal inflow modulation (PIM) therapy, effectively reducing PVP in patients undergoing MH.
Area of Science:
- Hepatobiliary surgery
- Surgical physiology
- Pharmacological interventions
Background:
- Major hepatectomy (MH) can elevate portal vein pressure (PVP), potentially impacting postoperative outcomes.
- High post-MH PVP is linked to adverse surgical results, necessitating effective portal inflow modulation (PIM) strategies.
- While surgical PIM techniques exist, pharmacological options like somatostatin show promise in experimental models.
Purpose of the Study:
- To evaluate the efficacy of somatostatin as a pharmacological portal inflow modulation (PIM) agent in patients undergoing major hepatectomy (MH).
- To assess the impact of somatostatin on portal vein pressure (PVP) in patients with elevated post-hepatectomy PVP (> 20 mmHg).
Main Methods:
- A clinical study involving 10 patients who underwent MH with post-hepatectomy PVP > 20 mmHg.
- Administration of somatostatin for portal inflow modulation (PIM).
- Monitoring of portal vein pressure (PVP) changes before and after somatostatin administration.
Main Results:
- Somatostatin administration resulted in a decrease in portal vein pressure (PVP).
- The study suggests somatostatin could be an effective PIM strategy, with a PVP decrease exceeding 2.5 mmHg observed.
- The effect of somatostatin on PVP was reversible.
Conclusions:
- Somatostatin shows potential as an efficient and reversible pharmacological portal inflow modulation (PIM) agent.
- This study provides the first clinical evidence for somatostatin's use in managing elevated PVP after major hepatectomy (MH).
- Further research is warranted to confirm somatostatin's role in improving postoperative outcomes following MH.
